SGHT guidance is weak and hopefully a reflection of them losing share.
"Sight Sciences projects revenue for full year 2024 to range from approximately $81.0 million to $85.0 million, representing a range of 0% to 5% growth compared to 2023. The Company expects double-digit revenue growth in the second half of 2024 versus the comparable periods in the prior year as it regains commercial momentum and expands utilization and its customer base."
Nova Eye Medical (EYE) Discussion, page-2412
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.025(11.6%) |
Mkt cap ! $54.91M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 25.0¢ | 22.0¢ | $250.2K | 1.070M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 3900 | 1 |
View Market Depth
| Last trade - 15.59pm 04/07/2024 (20 minute delay) ? |
| EYE (ASX) Chart |